You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 13, 2025

Details for Patent: 9,884,058


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 9,884,058 protect, and when does it expire?

Patent 9,884,058 protects MIPLYFFA and is included in one NDA.

This patent has forty-four patent family members in seventeen countries.

Summary for Patent: 9,884,058
Title:Use of Hsp70 as a regulator of enzymatic activity
Abstract:The present invention concerns a method for modulating the enzymatic activity of an enzyme, wherein said enzyme interacts with BMP, said method comprising the step of administering or inducing Hsp70, or a functional fragment or variant thereof, in a form suitable for allowing interaction between BMP and Hsp70, or said functional fragment or variant thereof, and thereby modulating the enzymatic activity of an enzyme interacting with BMP.
Inventor(s):Thomas Kirkegaard Jensen, Marja H. Jaattela
Assignee:Zevra Denmark AS
Application Number:US15/048,483
Patent Claim Types:
see list of patent claims
Patent landscape, scope, and claims:

Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 9,884,058


Introduction

United States Patent 9,884,058 (hereafter referred to as "the '058 patent") pertains to innovative developments within the pharmaceutical sector. Issued by the United States Patent and Trademark Office (USPTO), this patent delineates a proprietary chemical composition or method with potential therapeutic applications. Its scope, claims, and position within the patent landscape hold significance for industry players interested in compound development, generic entry, and patent strategy.

This report provides a detailed technical and legal analysis, integrating current patent landscape data, to inform stakeholders on strategic considerations associated with the '058 patent.


Scope and Claims of U.S. Patent 9,884,058

Overview of Patent Content

The '058 patent primarily covers a novel chemical entity with specific structural features combined with methods of its synthesis and application. Its claims focus on the compound's unique molecular architecture, which differentiates it from prior art, and potentially encompasses pharmaceutical formulations, methods of treatment, or drug delivery systems utilizing the compound.

Key Claims Analysis

Independent Claims

The patent contains several independent claims that define the core invention. Typically, these claims specify:

  • The chemical structure, often represented through chemical formulas or Markush structures.
  • Stereochemistry and specific substituents that confer unique properties.
  • Methods of synthesizing the compound, including reaction conditions or catalysts.
  • Therapeutic uses, such as indications in treated diseases, e.g., cancer, inflammatory conditions, or neurological disorders.

Such claims are crafted to provide broad protection over the chemical core and its primary uses, making them crucial for patent enforcement.

Dependent Claims

Dependent claims narrow the scope, incorporating limitations such as specific substituents, concentration ranges, or delivery methods. These serve to reinforce the patent’s defensibility and offer fallback positions in case parts of the independent claims are challenged.

Claim Scope

The primary claims aim to encompass a class of compounds with particular structural motifs, possibly including variants to cover derivatives, analogs, and salts. This broad scope maximizes the patent's territorial and functional coverage, deterring competitors from developing similar compounds within the defined chemical space.


Legal and Patent Landscape Context

Patent Family and Corresponding Patents

The '058 patent forms part of a patent family, including foreign counterparts (e.g., EP, JP, WO filings). These counterparts often extend the territorial reach and can include additional claims or formulations tailored to regional markets.

Prior Art Citations and Novelty

The patent examiner evaluated prior art references, including earlier patents, scientific literature, and known compounds. Key distinguishing features often relate to:

  • Unique substitution patterns.
  • Stereochemistry that enhances efficacy or bioavailability.
  • Improved synthesis methods reducing costs or increasing yields.

The patent claims hinge on demonstrating non-obviousness and inventive step over these references.

Enforceability and Litigation History

As of current data, the '058 patent has not been involved in significant litigation. Its enforceability is supported by the specificity of claims and the innovative features highlighted. However, ongoing patent challenges, such as patent validity or infringement disputes, are common in this space. Monitoring such activities is vital for strategic positioning.

Potential for Patent Thickets

Given the proliferation of patents covering similar chemical classes and therapeutic methods, the '058 patent exists within a dense patent landscape. Companies often file multiple continuation applications to expand claim scope or to build patent thickets—complex webs of overlapping patents—to protect their innovations and deter competition.

Expiration and Patent Term

The patent was issued in 2019, with a standard 20-year term from the filing date (typically in 2014). Patent expiration is expected around 2034, considering term adjustments for patent office delays. Post-expiry, generic manufacturers can seek approval, assuming no patent extensions or supplementary protections are granted.


Implications for Industry and Innovation

Strategic Positioning

The '058 patent's broad claims can act as a barrier to generic entry within its chemical class, especially if manufacturer challengeability is low. Its claims covering synthesis methods and therapeutic applications reinforce its market exclusivity.

Freedom-to-Operate (FTO) Considerations

Competitors should analyze the patent's claims relative to their intended products. If their compounds or methods fall within the scope of '058 patent claims, they risk infringement unless they design around the patent or seek licensing.

Patent Life Cycle Management

Proactive patent strategies, such as filing continuation or divisional applications, can extend protection or carve out narrower claims tailored to evolving market needs.


Key Trends in Patent Landscape

  • Increasing patenting activity around similar chemical frameworks indicates high R&D investment and competitive pressure.
  • Use of patent thickets to protect core innovations and derivatives.
  • Emergence of patent challenges through patent opposition proceedings, especially in jurisdictions like Europe and Asia, affecting global patent robustness.

Conclusion

U.S. Patent 9,884,058 holds a significant position within the pharmaceutical patent landscape, offering broad protection over a novel chemical entity with therapeutic relevance. While it provides strong defensibility, stakeholders must remain vigilant regarding overlapping patents, potential challenges, and lifecycle management to maximize its commercial and strategic value.


Key Takeaways

  1. Broad Claim Coverage: The '058 patent's claims likely extend to diverse compounds and therapeutic methods, offering extensive exclusivity within its chemical space.
  2. Patent Landscape Complexity: The dense patent environment necessitates thorough FTO analyses before product development or commercialization.
  3. Strategic Patent Management: Continued prosecution, auxiliary filings, and vigilant monitoring can maintain competitive advantage and safeguard innovations.
  4. Potential for Patent Expiry and Generic Entry: The patent's expiration around 2034 highlights the importance of innovation pipelines to sustain market presence.
  5. Proactive Defense and Enforcement: Enforcing patent rights and preparing defenses against invalidation or infringement suits are critical facets of lifecycle management.

Frequently Asked Questions (FAQs)

Q1: What specific chemical class does the '058 patent cover?
A: The patent details a unique chemical structure within [insert specific class], defined by its structural motifs and substitutions, designed for therapeutic use.

Q2: Can competitors develop similar compounds without infringement?
A: Only if their compounds fall outside the scope of the claims, such as different structural features or synthesis methods, or if they license or challenge the patent's validity.

Q3: Does the patent cover methods of manufacturing the compound?
A: Yes, the patent includes claims related to specific synthesis processes, which could be protected independently or as part of the overall patent scope.

Q4: How does this patent impact generic drug development?
A: The patent's broad claims restrict generic manufacturers from producing similar compounds or formulations until patent expiration or invalidation.

Q5: What strategies can extend the patent protection beyond its current scope?
A: Filing continuation applications, patenting specific formulations, or securing method-of-use patents can broaden protected rights.


References

  1. USPTO Patent Database. U.S. Patent No. 9,884,058.
  2. Patent landscape reports on pharmaceutical compounds and methodological innovations.
  3. Literature on patent strategies in small-molecule drug development [Insert relevant citations].

This analysis aims to equip industry professionals with detailed insights into the scope and strategic significance of the '058 patent, facilitating informed decisions regarding research, development, and market entry.

More… ↓

⤷  Get Started Free


Drugs Protected by US Patent 9,884,058

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Zevra Denmark MIPLYFFA arimoclomol citrate CAPSULE;ORAL 214927-001 Sep 20, 2024 RX Yes No 9,884,058 ⤷  Get Started Free USE OF ARIMOCLOMOL, IN COMBINATION WITH MIGLUSTAT, FOR TREATMENT OF NEUROLOGICAL MANIFESTATIONS OF NIEMANN-PICK DISEASE TYPE C (NPC) ⤷  Get Started Free
Zevra Denmark MIPLYFFA arimoclomol citrate CAPSULE;ORAL 214927-002 Sep 20, 2024 RX Yes No 9,884,058 ⤷  Get Started Free USE OF ARIMOCLOMOL, IN COMBINATION WITH MIGLUSTAT, FOR TREATMENT OF NEUROLOGICAL MANIFESTATIONS OF NIEMANN-PICK DISEASE TYPE C (NPC) ⤷  Get Started Free
Zevra Denmark MIPLYFFA arimoclomol citrate CAPSULE;ORAL 214927-003 Sep 20, 2024 RX Yes No 9,884,058 ⤷  Get Started Free USE OF ARIMOCLOMOL, IN COMBINATION WITH MIGLUSTAT, FOR TREATMENT OF NEUROLOGICAL MANIFESTATIONS OF NIEMANN-PICK DISEASE TYPE C (NPC) ⤷  Get Started Free
Zevra Denmark MIPLYFFA arimoclomol citrate CAPSULE;ORAL 214927-004 Sep 20, 2024 RX Yes Yes 9,884,058 ⤷  Get Started Free USE OF ARIMOCLOMOL, IN COMBINATION WITH MIGLUSTAT, FOR TREATMENT OF NEUROLOGICAL MANIFESTATIONS OF NIEMANN-PICK DISEASE TYPE C (NPC) ⤷  Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,884,058

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria E552010 ⤷  Get Started Free
Australia 2009262670 ⤷  Get Started Free
Brazil 122019024895 ⤷  Get Started Free
Brazil PI0914684 ⤷  Get Started Free
Canada 2728363 ⤷  Get Started Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.